Humana Press has released High Content Screening, a textbook from its “Methods in Molecular Biology” series.
High Content Screening is edited by Lansing Taylor, president, CEO, and co-founder of Cellumen, and co-founder and former chairman and CEO of Cellomics; Jeffrey Haskins, vice president of technology and product development at Cellomics; and Kenneth Giuliano, a principal scientist at Cellomics.
Invitrogen has introduced Lipofectamine LTX, a transfection reagent for DNA delivery.
According to the company, the reagent demonstrates high levels of transfection efficiency and protein expression with more than 90 percent viability for a wide range of cells, including primary neuronal cells and other disease-relevant cell types.
Caliper Life Sciences last week unveiled its Xenogen IVIS Spectrum imaging system. The Xenogen system is the only in vivo optical imaging system that can perform high sensitivity bioluminescent imaging and advanced fluorescent imaging, the company said in a statement. Its dual illumination capability “enables tomographic localization of both shallow and deep tumors in 3D and reduces background interference,” Caliper said.
Caliper is currently taking orders for the IVIS Spectrum, which will be available in the first quarter of 2007.